TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3053555

Group type: EXPERIMENTAL
Intervention: Cefoperazone + netilmicin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Mezlocillin + netilmicin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Piperacillin + netilmicin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Ticarcillin + netilmicin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 174
Study: 31982002

Group type: EXPERIMENTAL
Intervention: Random time session
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Random direction session
Number of subjects: 15

Group type: COMPARATOR
Intervention: Constant session
Number of subjects: 15
Study: 30973263

Group type: EXPERIMENTAL
Intervention: Anesthetic block to one finger
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile perceptual training during anesthetic block of the neighboring finger
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham block with saline
Number of subjects: 0
Study: 28777224

Group type: EXPERIMENTAL
Intervention: 1.25 mg intracameral bevacizumab
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intraoperative mitomycin C (MMC)
Number of subjects: 87
Study: 26646828

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy programme
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 34
Study: 23550668

Group type: EXPERIMENTAL
Intervention: Amphotericin B plus flucytosine
Number of subjects: 299

Group type: COMPARATOR
Intervention: Amphotericin B alone
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Amphotericin B plus fluconazole
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 299
Study: 16943462

Group type: EXPERIMENTAL
Intervention: Palamed G
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palacos R with gentamicin
Number of subjects: 60
Study: 14687360

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Computerized Balance Training (BT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Education (ED)
Number of subjects: 200
Study: 10809243

Group type: EXPERIMENTAL
Intervention: Immediate full-volume exchange (2000 mL) per 6 hours from the day of catheter implantation (group 2)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Stepwise volume increment method (group 1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Immediate full-volume exchange (group 2)
Number of subjects: 59
Study: 8873503

Group type: EXPERIMENTAL
Intervention: Alendronate 40 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 1516840

Group type: EXPERIMENTAL
Intervention: cold perfusate + EC‐SOD C 10.4 mg/L (30,000 U/L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: cold perfusate only
Number of subjects: 40

Group type: COMPARATOR
Intervention: cold perfusate + bovine CuZn‐SOD 7.5 mg/L (30,000 U/L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: cold perfusate + EC‐SOD C 10.4 mg/L + heparin 50,000U/L
Number of subjects: 40

Group type: COMPARATOR
Intervention: cold perfusate + heparin 50,000 U/L
Number of subjects: 40

Group type: COMPARATOR
Intervention: cold perfusate only, cold perfusate + bovine CuZn‐SOD, cold perfusate + EC‐SOD C + heparin, cold perfusate + heparin
Number of subjects: 40
Study: 6707844

Group type: EXPERIMENTAL
Intervention: Full-strength cow's milk feeds after 24 hours of GEM treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gradual reintroduction of milk over 4 days
Number of subjects: 48
Study: 30362280

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Teneligliptin
Number of subjects: 201

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 201
Study: 28857654

Group type: EXPERIMENTAL
Intervention: Duloxetine therapy for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 25670530

Group type: EXPERIMENTAL
Intervention: Acerto protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional preoperative care
Number of subjects: 20
Study: 23418947

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (11% O2) for 4 hours after a light breakfast
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normoxia (control condition) for 4 hours after a light breakfast
Number of subjects: 15
Study: 21299296

Group type: EXPERIMENTAL
Intervention: Group and individual exercise, moderate and challenging workouts (yoga, Pilates, aerobic exercise, weight training)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Harnessing forecasting myopia
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Overcoming forecasting myopia
Number of subjects: 279
Study: 19857180

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Closed reduction and external fixation
Number of subjects: 50
Study: 17284128

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Fluoxetine (SSRI)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 88
Study: 15041596

Group type: EXPERIMENTAL
Intervention: Preincision ketamine 0.15 mg/kg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Postoperative ketamine 0.15 mg/kg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo saline IV
Number of subjects: 135
Study: 11306778

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9483158

Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trial (RCT) methodology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cultural or religious objections to RCTs
Number of subjects: 0
Study: 7942164

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 or 2000 mg Ca2+)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 248
Study: 2904754

Group type: EXPERIMENTAL
Intervention: Doxazosin (mean dose, 3.3 mg) once daily for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atenolol (100 mg) once daily for 8 weeks
Number of subjects: 40
Study: 29431256

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1322
Study: 28628884

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 102
Study: 26758116

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 2 mg/(kg·d) intravenously for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-steroid therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (20 cases with bronchial foreign body, no respiratory tract infection)
Number of subjects: 60
Study: 23768973

Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 100
Study: 22028266

Group type: EXPERIMENTAL
Intervention: Fendrix (20 micrograms, 4 doses)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Engerix B (40 micrograms, 3 doses with optional booster)
Number of subjects: 92
Study: 18081807

Group type: EXPERIMENTAL
Intervention: Gutta‐percha/Ketac‐Endo/cold lateral compaction
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Gutta‐percha/AH Plus/cold lateral compaction
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany combinations
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Overall cohesive failures
Number of subjects: 144
Study: 16144849

Group type: EXPERIMENTAL
Intervention: Sodium profiling (DC 15.0‐‐>14.0 mS/cm)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Blood volume (BV)-controlled feedback
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PC-controlled feedback
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard HD (dialysate conductivity DC 14.0 mS/cm)
Number of subjects: 10
Study: 14629289

Group type: EXPERIMENTAL
Intervention: Immediate initiation of cyclosporine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Delayed initiation of cyclosporine
Number of subjects: 56
Study: 11185674

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg QD for 10 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg once daily on days 4 through 10) with Rofecoxib
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (for 10 days)
Number of subjects: 24
Study: 9174467

Group type: EXPERIMENTAL
Intervention: Emmental cheese
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Calcium salt (calcium lactate gluconate + calcium carbonate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control session (no additional calcium)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sesame seeds
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Spinach
Number of subjects: 9
Study: 1550149

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 140
Study: 2860386

Group type: EXPERIMENTAL
Intervention: 1 mg CL115,347/day transdermally for 6 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30624598

Group type: EXPERIMENTAL
Intervention: 6-month hypocaloric, nutritionally complete, higher-protein meal plan targeting ≥1.0 g protein · kg body weight-1 · d-1 (WL group; n=47)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Weight-stability (WS) group targeting 0.8 g protein · kg body weight-1 · d-1 (n=49)
Number of subjects: 96
Study: 29739634

Group type: EXPERIMENTAL
Intervention: Mindfulness-based exposure and response prevention (MB-ERP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Exposure and response prevention (ERP)
Number of subjects: 37
Study: 26993331

Group type: EXPERIMENTAL
Intervention: C. difficile vaccine formulations (toxoids A and B) administered at antigen dose levels of 50, 100, or 200 μg in a 3-dose regimen at 0, 1, and 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 24495158

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 725
Study: 22782417

Group type: EXPERIMENTAL
Intervention: Acadesine (0.1 mg/kg per minute for 7 hours)
Number of subjects: 3080

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3080
Study: 21311486

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (copaxone) 20 mg/d for 4.3±2.6 years
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (patients without MS)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Patients with confirmed MS in remission not treated with disease-modifying drugs
Number of subjects: 158
Study: 17433949

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary balloon angioplasty (PTCA)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1829
Study: 16309127

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 220

Group type: COMPARATOR
Intervention: Lofexidine hydrochloride (Control)
Number of subjects: 220
Study: 12044618

Group type: EXPERIMENTAL
Intervention: Headache pain during encoding
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Headache pain during memory task
Number of subjects: 80

Group type: COMPARATOR
Intervention: No headache pain during encoding
Number of subjects: 80

Group type: COMPARATOR
Intervention: No headache pain during memory task
Number of subjects: 80
Study: 10332798

Group type: EXPERIMENTAL
Intervention: Active rehabilitation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Passive control treatment
Number of subjects: 59
Study: 8949690

Group type: EXPERIMENTAL
Intervention: 95% oxygen saturation (SpO2)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 90% oxygen saturation (SpO2)
Number of subjects: 13
Study: 2044395

Group type: EXPERIMENTAL
Intervention: 200 mg bencyclane twice daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 6796714

Group type: EXPERIMENTAL
Intervention: Liposyn 10%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intralipid 10%
Number of subjects: 13
Study: 30477552

Group type: EXPERIMENTAL
Intervention: Health-enhancing physical activity (HEPA) support program
Number of subjects: 30
Study: 28644575

Group type: EXPERIMENTAL
Intervention: Levofloxacin plus bismuth‐based quadruple therapy (RBAL)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Levofloxacin‐based triple therapy (RAL)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 67
Study: 26271275

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 50

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 50
Study: 23984728

Group type: EXPERIMENTAL
Intervention: Macitentan 3 mg
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 742

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study: 21390215

Group type: EXPERIMENTAL
Intervention: Using a stick to touch the object
Number of subjects: 6

Group type: COMPARATOR
Intervention: Using a hand to touch the object
Number of subjects: 6
Study: 18326123

Group type: EXPERIMENTAL
Intervention: 20‐minute writing task
Number of subjects: 71
Study: 16860698

Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (efavirenz, EFV)
Number of subjects: 911

Group type: COMPARATOR
Intervention: Protease inhibitor (nelfinavir, NFV)
Number of subjects: 911

Group type: COMPARATOR
Intervention: Both (EFV/NFV)
Number of subjects: 911
Study: 12664518

Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oral Tramadol 0.5 mg/kg/6 hours for 24 hours
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (32 children with one dose of Tramadol 2 mg/kg)
Number of subjects: 72
Study: 10326070

Group type: EXPERIMENTAL
Intervention: Fractal analysis of trabecular bone texture on calcaneus radiographs
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Femoral neck bone mineral density (FNBMD)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trochanteric bone mineral density (TRBMD)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve for Hmean
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fractal analysis in overlapping subgroups of FNBMD or TRBMD
Number of subjects: 39
Study: 8948740

Group type: EXPERIMENTAL
Intervention: Plasmapheresis with cell saver
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intraoperative autotransfusion
Number of subjects: 50
Study: 2565999

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 32
Study: 1108694

Group type: EXPERIMENTAL
Intervention: Epidural injection of 20-25 ml of normal saline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 150
Study: 7406657

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate (single oral dose)
Number of subjects: 0
Study: 31831801

Group type: EXPERIMENTAL
Intervention: N95 mask without micro ventilator (MF)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: N95 mask with micro ventilator (MF)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: N95 mask with and without MF
Number of subjects: 106
Study: 28343801

Group type: EXPERIMENTAL
Intervention: RUTF (Ready-to-Use Therapeutic Food)
Number of subjects: 68

Group type: COMPARATOR
Intervention: ONS (Oral Nutritional Supplements)
Number of subjects: 68
Study: 26273900

Group type: EXPERIMENTAL
Intervention: Oatmeal
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ready-to-eat oat-based breakfast cereal (RTEC)
Number of subjects: 48
Study: 25074698

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - inflation of a blood pressure cuff on the left thigh to 15 mm Hg above systolic for four 5‐minute intervals
Number of subjects: 299

Group type: COMPARATOR
Intervention: Sham stimulus (blinded)
Number of subjects: 299
Study: 21883811

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (1 g 12-h)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 18635696

Group type: EXPERIMENTAL
Intervention: SL65.1498 (three doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17244295

Group type: EXPERIMENTAL
Intervention: Cash and Counseling (treatment group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Directly hired workers (treatment group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Agency workers (control group)
Number of subjects: 0
Study: 14704597

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 12149661

Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 22
Study: 9800063

Group type: EXPERIMENTAL
Intervention: Frequent replacement soft contact lenses
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional daily wear soft contact lenses
Number of subjects: 2
Study: 8556087

Group type: EXPERIMENTAL
Intervention: Continuous thermodilution method
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intermittent thermodilution method
Number of subjects: 14
Study: 2104790

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 400862

Group type: EXPERIMENTAL
Intervention: Ritodrine combined with indomethacin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ritodrine and placebo
Number of subjects: 44
Study: 30824956

Group type: EXPERIMENTAL
Intervention: MYL‐1401H
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference pegfilgrastim
Number of subjects: 0
Study: 28860266

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 279
Study: 25223369

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 50, 100, 250, 500 or 1000 mg twice daily
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE)
Number of subjects: 336
Study: 23356455

Group type: EXPERIMENTAL
Intervention: Combined GP care and cognitive-behavioral intervention group (n = 54)
Number of subjects: 108

Group type: COMPARATOR
Intervention: GP care control group (n = 54)
Number of subjects: 108
Study: 21274703

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No-stress condition
Number of subjects: 79
Study: 19574102

Group type: EXPERIMENTAL
Intervention: 12-minute audio relaxation program
Number of subjects: 41

Group type: COMPARATOR
Intervention: 12-minute Mozart andante
Number of subjects: 41
Study: 17084549

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg twice daily) with concurrent cisplatin (75 mg/m2) and 5-FU (1g/m2 for 4 days) and pelvic radiation therapy
Number of subjects: 84
Study: 15159243

Group type: COMPARATOR
Intervention: T54 carriers
Number of subjects: 22

Group type: COMPARATOR
Intervention: T54 carriers after olive oil
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 22
Study: 11237478

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (26% fatty acid as LCPUFA including 4.6% gamma-linolenic acid, 7.4% arachidonic acid, 5.5% eicosapentaenoic acid, 8% DHA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 20
Study: 9876503

Group type: EXPERIMENTAL
Intervention: Phenylbutazone tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dissolution parameters
Number of subjects: 0
Study: 8011009

Group type: EXPERIMENTAL
Intervention: Multiple-unit formulation (Diclo-Puren 50)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single-unit formulation (reference)
Number of subjects: 12
Study: 2575369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/day and Cicletanine 100 mg/day
Number of subjects: 120
Study: 1190365

Group type: EXPERIMENTAL
Intervention: Metronidazole (2.5 g during 5 days to 7.5 g in 10 days for children; 5 g in 5 days or 12.5 g in 10 days for adults)
Number of subjects: 20
Study: 29888663

Group type: EXPERIMENTAL
Intervention: Dental treatment during pregnancy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dental examination (non-treated group)
Number of subjects: 150
Study: 29691569

Group type: EXPERIMENTAL
Intervention: Enclosed formaldehyde cresol (FC) with CAVITON‐GC after removal of crown pulp
Number of subjects: 223

Group type: COMPARATOR
Intervention: Open drainage
Number of subjects: 223
Study: 26156651

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg per day)
Number of subjects: 795
Study: 23774238

Group type: EXPERIMENTAL
Intervention: Sivelestat (0.2 mg/kg/hour continuous intravenous infusion)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 26
Study: 21114862

Group type: EXPERIMENTAL
Intervention: Free school breakfast programme (non-sugar coated breakfast cereal, milk products, and/or toast and spreads)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Free school breakfast programme
Number of subjects: 400